Study: ACA Expansion of 340B Not Driving Consolidation of Oncology Practices

by Admin | April 5, 2017 1:52 pm

April 5, 2017—Neither the expansion of the 340B drug discount program[1] made by the Affordable Care Act nor changes in Medicare Part B drug reimbursement policy are primary causes of the recent wave of private oncology practice consolidations with hospitals, says a new study[2] in Health Affairs.  Instead, the vertical amalgamation likely is part of a broader trend toward integrated healthcare.  

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[3].    Already registered? Click here to login[4]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Endnotes:
  1. 340B drug discount program: https://youtu.be/mo1pvJPOfas
  2. study: http://content.healthaffairs.org/content/36/4/680.abstract
  3. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  4. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2017/04/study-aca-expansion-of-340b-not-driving-consolidation-of-oncology-practices/

Copyright ©2024 340binformed.org unless otherwise noted.